

Pulmonary Sarcoidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/P29F7BE43300EN.html>

Date: May 2024

Pages: 128

Price: US\$ 6,499.00 (Single User License)

ID: P29F7BE43300EN

Abstracts

The 7 major pulmonary sarcoidosis markets reached a value of US\$ 17.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 53.3 Billion by 2034, exhibiting a growth rate (CAGR) of 10.6% during 2024-2034.

The pulmonary sarcoidosis market has been comprehensively analyzed in IMARC's new report titled "Pulmonary Sarcoidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pulmonary sarcoidosis refers to a chronic systemic condition in which the immune system becomes overreactive, producing lumps or nodules called granulomas. The disorder most commonly affects the lungs and lymph nodes but can also impact any other organ. The general indications associated with pulmonary sarcoidosis include fatigue, swollen lymph nodes, fever, a feeling of discomfort or illness, shortness of breath, cough, pain and swelling in the joints, unexplained weight loss, night sweats, depression, etc. In severe cases, the ailment can lead to fibrosis, resulting in permanent lung scarring among patients. The diagnosis of this condition is difficult as the symptoms are common in many other diseases. A physical exam, several imaging procedures, such as CT scan, MRI, chest X-ray, etc., and a biopsy of suspicious granulomas are commonly used to diagnose pulmonary sarcoidosis. The healthcare provider may also perform endobronchial ultrasound-guided transbronchial fine needle aspiration to rule out other health problems.

The increasing prevalence of respiratory disorders caused by exposure to smoke, dust, chemicals, etc., is primarily driving the pulmonary sarcoidosis market. Apart from this, the rising incidences of bacterial and viral infections, which can trigger the immune system to respond actively, are also bolstering the market growth. Furthermore, the

widespread adoption of anti-tumor necrosis factor-alpha antibodies and nonsteroidal anti-inflammatory drugs in disease treatment, since they reduce lung inflammation and boost overall health, is creating a positive outlook for the market. Besides this, the escalating utilization of immunosuppressants and corticosteroids, which work by modifying or suppressing the activity of the defense system and preventing disease progression, is also augmenting the market growth. Moreover, several key players are investing in R&D activities to innovate novel, cost-effective, and minimally invasive diagnostic tools that can aid in the early detection of disease among patients. This, in turn, is acting as another significant growth-inducing factor. Additionally, the ongoing development of subcutaneous human monoclonal antibodies, such as namilumab, that target granulocyte-macrophage colony-stimulating factors and provide quick symptom relief is expected to drive the pulmonary sarcoidosis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the pulmonary sarcoidosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pulmonary sarcoidosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pulmonary sarcoidosis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the pulmonary sarcoidosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the pulmonary sarcoidosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current pulmonary sarcoidosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the pulmonary sarcoidosis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the pulmonary sarcoidosis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the pulmonary sarcoidosis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of pulmonary sarcoidosis across the seven major markets?

What is the number of prevalent cases (2018-2034) of pulmonary sarcoidosis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of pulmonary sarcoidosis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with pulmonary sarcoidosis across the seven major markets?

What is the size of the pulmonary sarcoidosis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of pulmonary sarcoidosis?

What will be the growth rate of patients across the seven major markets?

Pulmonary Sarcoidosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for pulmonary sarcoidosis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pulmonary sarcoidosis market?

What are the key regulatory events related to the pulmonary sarcoidosis market?

What is the structure of clinical trial landscape by status related to the pulmonary sarcoidosis market?

What is the structure of clinical trial landscape by phase related to the pulmonary sarcoidosis market?

What is the structure of clinical trial landscape by route of administration related to the pulmonary sarcoidosis market?

Contents

?1 Preface

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study

2.2 Stakeholders

2.3 Data Sources

2.3.1 Primary Sources

2.3.2 Secondary Sources

2.4 Market Estimation

2.4.1 Bottom-Up Approach

2.4.2 Top-Down Approach

2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 PULMONARY SARCOIDOSIS - INTRODUCTION

4.1 Overview

4.2 Regulatory Process

4.3 Epidemiology (2018-2023) and Forecast (2024-2034)

4.4 Market Overview (2018-2023) and Forecast (2024-2034)

4.5 Competitive Intelligence

5 PULMONARY SARCOIDOSIS - DISEASE OVERVIEW

5.1 Introduction

5.2 Symptoms and Diagnosis

5.3 Pathophysiology

5.4 Causes and Risk Factors

5.5 Treatment

6 PATIENT JOURNEY

7 PULMONARY SARCOIDOSIS - EPIDEMIOLOGY AND PATIENT POPULATION

7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 PULMONARY SARCOIDOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 PULMONARY SARCOIDOSIS - UNMET NEEDS

10 PULMONARY SARCOIDOSIS - KEY ENDPOINTS OF TREATMENT

11 PULMONARY SARCOIDOSIS - MARKETED PRODUCTS

- 11.1 List of Pulmonary Sarcoidosis Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 PULMONARY SARCOIDOSIS - PIPELINE DRUGS

12.1 List of Pulmonary Sarcoidosis Pipeline Drugs Across the Top 7 Markets

12.1.1 Efizofitimod - aTyr Pharma

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 CMK 389 - Novartis

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

12.1.3 Namilumab - Kinevant Sciences GmbH

12.1.3.1 Drug Overview

12.1.3.2 Mechanism of Action

12.1.3.3 Clinical Trial Results

12.1.3.4 Safety and Efficacy

12.1.3.5 Regulatory Status

12.1.4 RLF 100 - Relief Therapeutics

12.1.4.1 Drug Overview

12.1.4.2 Mechanism of Action

12.1.4.3 Clinical Trial Results

12.1.4.4 Safety and Efficacy

12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. PULMONARY SARCOIDOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. PULMONARY SARCOIDOSIS – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 PULMONARY SARCOIDOSIS - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Pulmonary Sarcoidosis - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Pulmonary Sarcoidosis - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Pulmonary Sarcoidosis - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Pulmonary Sarcoidosis - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Pulmonary Sarcoidosis - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Pulmonary Sarcoidosis - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Pulmonary Sarcoidosis - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Pulmonary Sarcoidosis - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Pulmonary Sarcoidosis - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

- 15.6.2 Pulmonary Sarcoidosis - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Pulmonary Sarcoidosis - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Pulmonary Sarcoidosis - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Pulmonary Sarcoidosis - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Pulmonary Sarcoidosis - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Pulmonary Sarcoidosis - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Pulmonary Sarcoidosis - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Pulmonary Sarcoidosis - Access and Reimbursement Overview

16 PULMONARY SARCOIDOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 PULMONARY SARCOIDOSIS MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 PULMONARY SARCOIDOSIS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Pulmonary Sarcoidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/P29F7BE43300EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P29F7BE43300EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

